DAS28 — Disease Activity Score (RA)
Disease Activity Score in 28 joints for monitoring rheumatoid arthritis. Used to guide DMARD escalation and biologic eligibility.
Score interpretation
DAS28 <2.6: Remission
→ Maintain current DMARD therapy; consider gradual tapering if sustained remission >12 months
DAS28 2.6–3.2: Low disease activity
→ Continue current therapy; target remission if possible
DAS28 3.2–5.1: Moderate disease activity
→ Review and optimise conventional DMARDs; consider adding hydroxychloroquine/sulfasalazine/leflunomide
DAS28 >5.1: High disease activity
→ Escalate therapy; assess biologic eligibility (TNF inhibitor, IL-6 inhibitor, JAK inhibitor); refer to rheumatologist urgently
Interpretation bands for the DAS28. Apply clinical judgement and local guidance.
References
- Prevoo ML, et al. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995;38(1):44-48.
Related
Curated clinical cross-links plus same-class fallbacks.
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Methotrexate (Low-dose) · DMARD (Disease-Modifying Antirheumatic Drug) / Immunosuppressant
- Pindolol · Non-selective β-blocker (with intrinsic sympathomimetic activity)
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.